Posted by Michael Wonder on 06 Jan 2023
Vaxcyte’s VAX-24 granted FDA breakthrough therapy designation for the prevention of invasive pneumococcal disease in adults
5 January 2023 - Breakthrough therapy designation for 24 valent investigational pneumococcal conjugate vaccine candidate based on positive topline proof of concept data results in adults aged 18-64 that suggest potential best in class profile.
Vaxcyte announced today that the US FDA granted breakthrough therapy designation for VAX-24, the Company’s investigational 24 valent pneumococcal conjugate vaccine candidate for the prevention of invasive pneumococcal disease in adults.
